The Rockefeller University » Office of Sponsored Programs Administration

COVID-19 / coronavirus FOAs (as of 10/28/24)

If you wish to submit to any of these programs, please contact your
Sponsored Programs Officer right away.

NIH

Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)
(NOT-DE-23-004) multiple due dates

Notice of Special Interest (NOSI) Pediatric COVID-19 and Respiratory Viral Co-infection
(NOT-HL-22-004) for NHLBI, NIAID & NICHD grantees; multiple due dates

Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research
(NOT-MH-22-100) multiple due dates

Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy
(NOT-HL-23-003) multiple due dates

NIAID news articles (2/19/20, 4/1/20 & 4/15/20) on this topic

NIAID’s Multi-Pronged Response to the COVID-2019 Outbreak

Updates on NIAID Funding for SARS-CoV-2 and COVID-2019 Research

NIAID’s Research Response to COVID-19 & Additional Accommodations Accompanying COVID-19 Pandemic Response

NSF

Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-052)
The National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to rapid-covid19@nsf.gov .

Dear Colleague Letter: Sentinel Cells for Surveillance and Response to Emergent Infectious Diseases (Sentinels) (NSF 20-105) rolling deadline, proposals are reviewed as they are received

With this Dear Colleague Letter (DCL), we highlight the interest of existing programs in the Directorate for Biological Sciences (BIO) and the Directorate for Engineering (ENG) in interdisciplinary research for the development of novel biological platforms that are capable of sensing and responding to emerging infectious agents. The mechanism of sensing should be adaptable and or evolvable such that the sentinel cells, or other appropriate biotechnology solutions, are robust to a range of emergent threats, and/or can easily be reprogrammed and deployed once a new threat is identified. The platform's response should be one or more of the following: alert the user, destroy the threat, protect the host, initiate an immune response or other strategies that would ensure mitigation of the threat. Sentinel cells and organisms that detect and respond to infectious agents with expanding footprints in a host population or expanding host ranges are of particular interest, as the early detection of these infectious agents might have value in preventing future pandemics. In addition, fundamental science and technology that would lead to the development of the envisioned sentinel cells and organisms are also of interest. Investigators are encouraged not to be limited in their approach, but to think broadly about innovations leveraging biology and engineering to advance adaptable detection of emerging biological threats.

Other Federal agencies (applied research projects):

CDC
US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
LOI due April 8, 2022; application due May 9, 2022

Biomedical Advanced Research and Development Authority (BARDA) BAA
https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view

DOD/Dept of Army RFP for Development of Treatments for COVID-19
enhanced white paper due April 8, 2020

DOD/Congressionally Directed Medical Research Programs (CDMRP)
FY20 Peer Reviewed Medical Research Program (PRMRP)
Investigator-Initiated Research Award (for Emerging Viral Diseases and Respiratory Health)
Clinical Trial Award (for Emerging Viral Diseases and Respiratory Health)
Technology/Therapeutic Development Award (for Emerging Viral Diseases and Respiratory Health)
Various due dates in June

DOD
Newton Award for Transformative Ideas during the COVID-19 Pandemic
This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. 5/15/20 deadline

FDA
Innovation Award: COVID-19 and Health Equity (U01)
(RFA-FD-22-003) 11/29/21 deadline

Innovation Award: COVID-19 and Health Equity (U01)
(RFA-FD-23-009) 1/16/23 deadline

Foundations / Other

The Wellcome Trust has a COVID-19 funding program too – up to £2 million for a 2 year project
https://wellcome.ac.uk/funding/schemes/epidemic-preparedness-covid-19

This program is currently closed. Note that their focus is on applicants from low/middle income countries, but they’re also interested in disease pathogenesis research too.

LifeArc Coronavirus (COVID-19) Therapeutics - initial £10M commitment for the identification of therapeutics that can be rapidly deployed to treat COVID-19; April 6, 2020 due date.

American Heart Association
Rapid Response Grant COVID-19 and Its Cardiovascular Impact April 6, 2020 due date.
Mechanisms Underlying Cardiovascular Consequences Associated with COVID-19 and Long COVID February 1, 2022 due date.

Emergent Ventures Fast Grants for COVID-19 Science - grant budgets range from $10K - $500K; $40M commitment from funders. This program has been paused.

American Lung Association COVID-19 and Emerging Respiratory Viruses Research Award The award ($100K/year for 2 years) is intended to support independent investigators with a stellar track record of accomplishment, who have the potential to advance our knowledge of COVID-19 and other novel respiratory viruses with epidemic potential. LOI September 22, 2023; full application (by invitation only) due December 15, 2023.

Gates Foundation COVID-19 Therapeutics Accelerator is a collaborative effort to research, develop and bring effective treatments to market quickly and accessibly. We are actively seeking and welcoming new partners and collaborators in this effort. This opportunity may involve intellectual property issues. Please contact Jeanne Farrell (Associate Vice President, jfarrell@rockefeller.edu) before submitting ideas.

Gates Foundation Grand Challenges ICODA COVID-19 Data Science program aims to unite data and develop processes, analytical tools and infrastructure to achieve rapid scientific progress and impact. Up to $100,000 for 1 year. January 19, 2021 deadline.

American Diabetes Association COVID-19 and Diabetes Research Award for research focused on the impact of diabetes on COVID-19 and the impact of COVID-19 on diabetes and its complications. Funding at least 10 grants of up to $100,000 each. May 22, 2020 deadline.

Pfizer Global Medical Grants Vaccine Preventable Diseases – COVID-19 to support research to increase knowledge of COVID-19 epidemiology, infection, pathophysiology, and potential prevention measures. $50,000 - $250,000/award; rolling deadline, RFP closed 6/17/2020

Expired NIH announcements

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)
(NOT-AI-20-030) for NIAID & NIGMS grantees - rescinded 4/8/20

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
(NOT-HL-20-757) for NHLBI grantees, FAQs , expired 5/15/20

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-034) for NIAID awardees ; rescinded – replaced with NOT-AI-20-059

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
(NOT-HG-20-030) for NHGRI awardees, May 15, 2020 deadline

Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
(NOT-AI-20-031) from NIAID – rescinded 5/14/20

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)
(NOT-DC-20-004) for NIDCD awardees, 6/1/20 deadline

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK
(NOT-DK-20-018) for NIDDK awardees, 6/1/20 deadline

Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)
(NOT-CA-20-042) for NCI awardees, 6/25/20 deadline

Notice of Special Interest (NOSI): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19
(NOT-GM-20-027) for NIGMS U24 awardees, 5/5/20 deadline

Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for the Establishment and Maintenance of a Research Database for Neurological Manifestations of the SARS-CoV-2
(NOT-NS-20-046) for NINDS U01 or U24 data center awardees, 5/8/20 deadline

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
(NOT-RM-20-015) for Common Fund awardees (e.g. DP2, R01, R35, U01, U54, etc), expired 6/20/20

Request for Proposals (RFP) Solicitation S20-119: Serological Sciences Network Capacity Building Centers
(NOT-CA-20-077) 7/16/20 deadline

Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)
(RFA-CA-20-038) 7/22/20 deadline

Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)
(RFA-CA-20-039) 7/22/20 deadline

Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)
(RFA-OD-20-013) 8/7/20 deadline

Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
(NOT-OD-20-120) 8/7/20 deadline

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01)
(PAR-20-178) from NIAID; applications will be accepted on a rolling basis, expiring 8/14/2020

Notice of Special Interest (NOSI): National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19)
(NOT-CA-20-082) 8/14/20 deadline

Notice of Special Interest (NOSI): Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19)
(NOT-AT-20-012) for NCCIH awardees, 8/17/20 deadline

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Wastewater Surveillance Research for Public Health Response to Coronavirus Disease 2019 (COVID-19).
(NOT-OD-20-159) 8/21/20 deadline

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)
(PAR-20-237) 8/28/20 deadline

Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
(NOT-AI-20-051) from NIAID, expired 9/8/20

Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)
(RFA-OD-20-014) 9/15/20 deadline

Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed)
(RFA-OD-20-015) 9/15/20 deadline

Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)
(RFA-OD-20-022) 9/15/20 deadline

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool
(NOT-OD-20-152) 9/15/20 deadline

Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)
(RFA-OD-20-017) 9/18/20 deadline

Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)
(RFA-OD-20-018) 9/18/20 deadline

NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional)
(RFA-RM-20-020) 9/30/2020 deadline, FAQs

Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)
(RFA-OD-20-016) 9/30/20 deadline

Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)
(RFA-OD-20-019) 9/30/20 deadline

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)
(RFA-OD-20-023) 9/30/20 deadline

04/09/2020

2020 NIAID Omnibus Broad Agency Announcement

Details

Contract

NIH/NIAID

NIAID estimates that the average annual total cost is $2M per contract, however, the total cost may vary depending upon the scope of the project

Other related existing NIH programs:
Partnerships for Countermeasures against Select Pathogens (R01)due date 6/29/20
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-028.htmlfrom NIAID